Wharton's jelly or bone marrow mesenchymal stromal cells improve cardiac function following myocardial infarction for more than 32 weeks in a rat model: A preliminary report

Current Stem Cell Research and Therapy

Volumn 8, Issue 1, 2013, Pages 46-59

  López, Yelica ^a   Lutjemeier, Barbara ^a   Seshareddy, Kiran ^a   Trevino, Elizabeth M ^a   Sue Hageman, K ^a   Musch, Timothy I ^a   Borgarelli, Michele ^a   Weiss, Mark L ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

Bone marrow; Cardiomyocyte differentiation; Cellular therapy; Echocardiography; Mesenchymal stromal cells; Myocardial ischemia; Preclinical testing; Rat; Regenerative medicine; Umbilical cord; Wharton's jelly

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; COCULTURE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL; THERAPY EFFECT; TREATMENT DURATION; WHARTON JELLY;

ANIMALS; BONE MARROW; CELL DIFFERENTIATION; CELL SEPARATION; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; FETUS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; RATS; WHARTON JELLY;

EID: 84877070464     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X11308010007     Document Type: Article

References (91)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367(9524): 1747-57.
2. Penn MS. Stem-cell therapy after acute myocardial infarction: the focus should be on those at risk. Lancet 2006; 367(9505): 87-8.
3. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature 2008; 451(7181): 937-42.
4. Tendera M, Wojakowski W. Clinical trials using autologous bone marrow and peripheral blood-derived progenitor cells in patients with acute myocardial infarction. Folia Histochem Cytobiol 2005; 43(4): 233-5.
5. Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106(24): 3009-17.
6. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006; 367(9505): 113-21.
7. Kang S, Yang YJ, Li CJ, Gao RL. Effects of intracoronary autologous bone marrow cells on left ventricular function in acute myocardial infarction: a systematic review and meta-analysis for randomized controlled trials. Coron Artery Dis 2008; 19(5): 327-35.
8. Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355(12): 1210-21.
9. Engelmann MG, Theiss HD, Hennig-Theiss C, et al. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J Am Coll Cardiol 2006; 48(8): 1712-21.
10. Ince H, Nienaber CA. Granulocyte-colony-stimulating factor in acute myocardial infarction: future perspectives after FIRSTLINEAMI and REVIVAL-2. Nat Clin Pract Cardiovasc Med 2007; 4 Suppl 1: S114-S118.
11. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006; 355(12): 1199-209.
12. Ripa RS, Jorgensen E, Wang Y, et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebocontrolled stem cells in myocardial infarction (STEMMI) trial. Circulation 2006; 113(16): 1983-92.
13. Zohlnhofer D, Ott I, Mehilli J, et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 2006; 295(9): 1003-10.
14. Povsic TJ, O'Connor CM. Cell therapy for heart failure: the need for a new therapeutic strategy. Expert Rev Cardiovasc Ther 2010; 8(8): 1107-26.
15. Barlow S, Brooke G, Chatterjee K, et al. Comparison of human placenta-and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev 2008; 17(6): 1095-107.
16. Battula VL, Bareiss PM, Treml S, et al. Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation. Differentiation 2007; 75(4): 279-91.
17. Li CD, Zhang WY, Li HL, et al. Isolation and Identification of a Multilineage Potential Mesenchymal Cell from Human Placenta. Placenta 2005 Sep 17. [Epub ahead of print].
18. Montesinos JJ, Flores-Figueroa E, Castillo-Medina S, et al. Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression. Cytotherapy 2009; 11(2): 163-76.
19. Pilz GA, Ulrich C, Ruh M, et al. Human term placenta-derived mesenchymal stromal cells are less prone to osteogenic differentiation than bone marrow-derived mesenchymal stromal cells. Stem Cells Dev 2011; 20(4): 635-46.
20. Erickson GR, Gimble JM, Franklin DM, Rice HE, Awad H, Guilak F. Chondrogenic potential of adipose tissue-derived stromal cells in vitro and in vivo. Biochem Biophys Res Commun 2002; 290(2): 763-9.
21. Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimble JM. Surface protein characterization of human adipose tissue-derived stromal cells. J Cell Physiol 2001; 189(1): 54-63.
22. Halvorsen YC, Wilkison WO, Gimble JM. Adipose-derived stromal cells--their utility and potential in bone formation. Int J Obes Relat Metab Disord 2000; 24 Suppl 4: S41-S44.
23. Safford KM, Hicok KC, Safford SD, et al. Neurogenic differentiation of murine and human adipose-derived stromal cells. Biochem Biophys Res Commun 2002; 294(2): 371-9.
24. Troyer DL, Weiss ML. Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells 2008; 26(3): 591-9.
25. Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 2007; 25(6): 1384-92.
26. Can A, Karahuseyinoglu S. Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells 2007; 25(11): 2886-95.
27. Lu LL, Liu YJ, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesissupportive function and other potentials. Haematologica 2006; 91(8): 1017-26.
28. Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells 2005; 23(2): 220-9.
29. Weiss ML, Troyer DL. Stem cells in the umbilical cord. Stem Cell Rev 2006;2(2):155-62.
30. Weiss ML, Anderson C, Medicetty S, et al. Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells 2008; 26(11): 2865-74.
31. Angelucci S, Marchisio M, Di GF, et al. Proteome analysis of human Wharton's jelly cells during in vitro expansion. Proteome Sci 2010; 8: 18.
32. Dominici M, Le BK, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4): 315-7.
33. Yang Z, Schmitt JF, Lee EH. Immunohistochemical analysis of human mesenchymal stem cells differentiating into chondrogenic, osteogenic, and adipogenic lineages. Methods Mol Biol 2011; 698: 353-66.
34. Choong PF, Mok PL, Cheong SK, Leong CF, Then KY. Generating neuron-like cells from BM-derived mesenchymal stromal cells in vitro. Cytotherapy 2007; 9(2): 170-83.
35. Mitchell KE, Weiss ML, Mitchell BM, et al. Matrix cells from Wharton's jelly form neurons and glia. Stem Cells 2003; 21(1): 50-60.
36. Anzalone R, Lo IM, Corrao S, et al. New emerging potentials for human Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. Stem Cells Dev 2010; 19(4): 423-38.
37. Anzalone R, Lo IM, Loria T, et al. Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Rev 2011; 7(2): 342-63.
38. Asumda FZ, Chase PB. Nuclear cardiac troponin and tropomyosin are expressed early in cardiac differentiation of rat mesenchymal stem cells. Differentiation 2012; 83(3): 106-15.
39. Guan J, Wang F, Li Z, et al. The stimulation of the cardiac differentiation of mesenchymal stem cells in tissue constructs that mimic myocardium structure and biomechanics. Biomaterials 2011; 32(24): 5568-80.
40. Grabowska I, Brzoska E, Gawrysiak A, et al. Restricted myogenic potential of mesenchymal stromal cells isolated from umbilical cord. Cell Transplant 2012; 21(8): 1711-26.
41. Lee JH, Kosinski PA, Kemp DM. Contribution of human bone marrow stem cells to individual skeletal myotubes followed by myogenic gene activation. Exp Cell Res 2005; 307(1): 174-82.
42. Shi D, Reinecke H, Murry CE, Torok-Storb B. Myogenic fusion of human bone marrow stromal cells, but not hematopoietic cells. Blood 2004; 104(1): 290-4.
43. Koninckx R, Hensen K, Daniels A, et al. Human bone marrow stem cells co-cultured with neonatal rat cardiomyocytes display limited cardiomyogenic plasticity. Cytotherapy 2009; 11(6): 778-92.
44. Martin-Rendon E, Sweeney D, Lu F, Girdlestone J, Navarrete C, Watt SM. 5-Azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes in vitro at high frequencies. Vox Sang 2008; 95(2): 137-48.
45. Asumda FZ, Chase PB. Age-related changes in rat bone-marrow mesenchymal stem cell plasticity. BMC Cell Biol 2011; 12: 44.
46. Seshareddy K, Troyer D, Weiss ML. Method to isolate mesenchymal-like cells from Wharton's Jelly of umbilical cord. Methods Cell Biol 2008; 86: 101-19.
47. Musch TI, Terrell JA. Skeletal muscle blood flow abnormalities in rats with a chronic myocardial infarction: rest and exercise. Am J Physiol 1992; 262(2 Pt 2): H411-H419.
48. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4): 315-7.
49. Halkos ME, Zhao ZQ, Kerendi F, et al. Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction. Basic Res Cardiol 2008; 103(6): 525-36.
50. Ma J, Ge J, Zhang S, et al. Time course of myocardial stromal cellderived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Res Cardiol 2005; 100(3): 217-23.
51. Wu KH, Zhou B, Yu CT, et al. Therapeutic potential of human umbilical cord derived stem cells in a rat myocardial infarction model. Ann Thorac Surg 2007; 83(4): 1491-8.
52. Li SC, Acevedo J, Wang L, et al. Mechanisms for progenitor cellmediated repair for ischemic heart injury. Curr Stem Cell Res Ther 2012; 7(1): 2-14.
53. ter Horst KW. Stem cell therapy for myocardial infarction: are we missing time? Cardiology 2010; 117(1): 1-10.
54. Wen Z, Zheng S, Zhou C, Wang J, Wang T. Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction. J Cell Mol Med 2011; 15(5): 1032-43.
55. Wollert KC, Drexler H. Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol 2010; 7(4): 204-15.
56. Le BK. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003; 5(6): 485-9.
57. Nasef A, Ashammakhi N, Fouillard L. Immunomodulatory effect of mesenchymal stromal cells: possible mechanisms. Regen Med 2008; 3(4): 531-46.
58. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006; 36(10): 2566-73.
59. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004; 95(1): 9-20.
60. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98(5): 1076-84.
61. Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol 2009; 217(2): 318-24.
62. Clarke E, McCann SR. Age dependent in vitro stromal growth. Bone Marrow Transplant 1989; 4(5): 596-7.
63. Paul D, Samuel SM, Maulik N. Mesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regeneration. Antioxid Redox Signal 2009; 11(8): 1841-55.
64. Tang YL, Zhao Q, Zhang YC, et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept 2004; 117(1): 3-10.
65. Zhang H, Fazel S, Tian H, et al. Increasing donor age adversely impacts beneficial effects of bone marrow but not smooth muscle myocardial cell therapy. Am J Physiol Heart Circ Physiol 2005; 289(5): H2089-H2096.
66. Arminan A, Gandia C, Bartual M, et al. Cardiac differentiation is driven by NKX2.5 and GATA4 nuclear translocation in tissuespecific mesenchymal stem cells. Stem Cells Dev 2009; 18(6): 907-18.
67. Hakuno D, Fukuda K, Makino S, et al. Bone marrow-derived regenerated cardiomyocytes (CMG Cells) express functional adrenergic and muscarinic receptors. Circulation 2002; 105(3): 380-6.
68. Huang Y, Zheng L, Gong X, et al. Effect of cyclic strain on cardiomyogenic differentiation of rat bone marrow derived mesenchymal stem cells. PLoS ONE 2012; 7(4): e34960.
69. Li Z, Guo X, Palmer AF, Das H, Guan J. High-efficiency matrix modulus-induced cardiac differentiation of human mesenchymal stem cells inside a thermosensitive hydrogel. Acta Biomater 2012; 8(10): 3586-95.
70. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103(5): 697-705.
71. Pereira WC, Khushnooma I, Madkaikar M, Ghosh K. Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation. J Tissue Eng Regen Med 2008; 2(7): 394-9.
72. Medvinsky A, Smith A. Stem cells: Fusion brings down barriers. Nature 2003; 422(6934): 823-5.
73. Zhang S, Wang D, Estrov Z, Raj S, Willerson JT, Yeh ET. Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo. Circulation 2004; 110(25): 3803-7.
74. Montesinos JJ, Flores-Figueroa E, Castillo-Medina S, et al. Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression. Cytotherapy 2009; 11(2): 163-76.
75. Krampera M, Marconi S, Pasini A, et al. Induction of neural-like differentiation in human mesenchymal stem cells derived from bone marrow, fat, spleen and thymus. Bone 2007; 40(2): 382-90.
76. Rosca AM, Burlacu A. Effect of 5-azacytidine: evidence for alteration of the multipotent ability of mesenchymal stem cells. Stem Cells Dev 2011; 20(7): 1213-21.
77. Wang HS, Hung SC, Peng ST, et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells 2004; 22(7): 1330-7.
78. Degeorge BR, Jr., Rosenberg M, Eckstein V, et al. BMP-2 and FGF-2 synergistically facilitate adoption of a cardiac phenotype in somatic bone marrow c-kit+/Sca-1+ stem cells. Clin Transl Sci 2008; 1(2): 116-25.
79. Li TS, Komota T, Ohshima M, et al. TGF-beta induces the differentiation of bone marrow stem cells into immature cardiomyocytes. Biochem Biophys Res Commun 2008; 366(4): 1074-80.
80. Li Z, Gu TX, Zhang YH. Hepatocyte growth factor combined with insulin like growth factor-1 improves expression of GATA-4 in mesenchymal stem cells cocultured with cardiomyocytes. Chin Med J (Engl) 2008; 121(4): 336-40.
81. Muscari C, Bonafe F, Carboni M, et al. Difluoromethylornithine stimulates early cardiac commitment of mesenchymal stem cells in a model of mixed culture with cardiomyocytes. J Cell Biochem 2008; 103(4): 1046-52.
82. Rota M, Kajstura J, Hosoda T, et al. Bone marrow cells adopt the cardiomyogenic fate in vivo. Proc Natl Acad Sci USA 2007; 104(45): 17783-8.
83. Yoon J, Choi SC, Park CY, et al. Bone marrow-derived side population cells are capable of functional cardiomyogenic differentiation. Mol Cells 2008; 25(2): 216-23.
84. La RG, Anzalone R, Corrao S, et al. Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. Histochem Cell Biol 2009; 131(2): 267-82.
85. Trivedi P, Tray N, Nguyen T, Nigam N, Gallicano GI. Mesenchymal stem cell therapy for treatment of cardiovascular disease: helping people sooner or later. Stem Cells Dev 2010; 19(7): 1109-20.
86. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011; 109(8): 923-40.
87. Cheng Z, Ou L, Zhou X, et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008; 16(3): 571-9.
88. Roddy GW, Oh JY, Lee RH, et al. Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-alpha stimulated gene/protein 6. Stem Cells 2011; 29(10): 1572-9.
89. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5(1): 54-63.
90. Borgarelli M, Savarino P, Crosara S, et al. Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med 2008; 22(1): 120-8.
91. Tanabe K, Yamaguchi K, Tani T, et al. Left atrial volume: predictor of atrial fibrillation in patients with degenerative mitral regurgitation. J Heart Valve Dis 2007; 16(1): 8-12.